Literature DB >> 1959988

Neutral glycosphingolipid expression in B-cell neoplasms.

A Kalisiak1, J G Minniti, E Oosterwijk, L J Old, D A Scheinberg.   

Abstract

The expression of neutral glycosphingolipids (GSL) in 37 B-cell neoplasms [7 acute lymphocytic leukemia (ALL), 5 Burkitt's lymphoma (BL), 7 chronic lymphocytic leukemia (CLL), 5 diffuse, poorly differentiated lymphoma (DPDL), 6 diffuse histiocytic lymphoma (DHL), 3 hairy-cell leukemia (HCL), and 4 multiple myeloma (MM)] was examined. Patterns of expression of simple (GlcCer, LacCer) and globo-series GSL (Gb3, Gb4) were found for each tumor type. In addition, pre-B ALL expressed the neo-lacto series GSL, paragloboside, which was not significantly seen at later stages of maturation. As a group, leukemias expressed about 10 times higher ratios of simple GSL to Globo-series GSL as compared to lymphomas, regardless of stage of differentiation. Significant amounts of GSL of other series were not found except in one CLL which contained asialo-GM2. GSL phenotype in these cells was not grossly affected by cell genotype since pre-B ALL containing Philadelphia chromosome t(9q;22q) translocations were similar to other ALL; and DHL with t(8q;14q) translocations had GSL patterns similar to other DHL samples and dissimilar to GSL patterns found in Burkitt's lymphomas with t(8q;14q). Differences in GSL expression among the different types of B-cell neoplasm suggested that GSL patterns form a phenotypic map that may complement the traditional glycoprotein immunophenotypic map and contribute to our understanding of the biology of these diseases and B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959988     DOI: 10.1002/ijc.2910490607

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells.

Authors:  D Miyamoto; T Ueno; S Takashima; K Ohta; T Miyawaki; T Suzuki; Y Suzuki
Journal:  Glycoconj J       Date:  1997-04       Impact factor: 2.916

2.  Biochemical, pathological and oncological relevance of Gb3Cer receptor.

Authors:  D Đevenica; V Čikeš Čulić; A Vuica; A Markotić
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

3.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

4.  Alpha 1,4galactosyltransferase activity and Gb3Cer expression in human leukaemia/lymphoma cell lines.

Authors:  C L Stults; R D Larsen; B A Macher
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

5.  Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.

Authors:  Adel Ersek; Anastasios Karadimitris; Nicole J Horwood
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-23       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.